Neuralgia, Postherpetic
Conditions
Keywords
Inclusion Criteria:Minimum of 4 on the Likert Pain Scale.If currently taking TCA and/or Gabapentin, need to have been on stable dose for minimum of 4 weeks., Exclusion Criteria:, Currently on any antiepilepic drugs (AED), except for Gabapentin., Currently taking opioid or unwilling to washout prior to the study,, Pregnant and lactating,, Have active severe systemic disease,, History of Stevens-Johnson syndrome or TEN,
Brief summary
To assess the efficacy of Lamictal for the treatment of pain and reduction of allodynia in patients with post herpetic neuralgia.
Interventions
DRUGLamictal in the treatment of Post-Herpetic Neuralgia
Sponsors
GlaxoSmithKline
George Washington University
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Inclusion criteria
* All patients will be over the age of 18, * Need to have a diagnosis of Post-Herpetic Neuralgia, * Minimum of 4 on the Likert Pain Scale, * If currently taking TCA and/or Gabapentin, need to have been on stable dose for minimum of 4 weeks
Exclusion criteria
* Currently on any antiepileptic drugs (AED), except for Gabapentin. * Currently taking opioid or unwilling to washout prior to the study, * Pregnant and lactating, * Have active severe systemic disease, * History of Stevens-Johnson syndrome or TEN, * Clinically significant abnormal lab values, * Known drug allergy to Lamictal, * Patients on Fibrates (Tricor and Lopid), * History of major psychiatric disturbance and substance abuse. * Valproate due to increase chances of severe rash, * Lidocaine Patch, * Use of hormonal contraceptives (birth control pills, patch, ring, injection)
Countries
United States
Outcome results
None listed